MAP Pharmaceuticals, Allergan

The $958 million acquisition of MAP Pharmaceuticals appears to target migraine sufferers whose pain resists the most common remedies. The acquiring firm, Allergan, Inc. already commands a leading...

Subscription required to view this article.

This content can only be accessed by FTCWatch subscribers. If you are an FTCWatch subscriber, please login to access this content

If you do not currently subscribe to FTCWatch please contact us for subscription information:

FTCWatch is delivered in the following formats: via email alert and online at